CIPH Ciphergen Biosystems (MM)

Leading Researchers Present Studies Utilizing Ciphergen's SELDI ProteinChip(R) Technology for Biomarker Discovery at the Annual American Association of Cancer Research (AACR) Meeting Ciphergen's PatternTrack(TM) Process of Biomarker Discovery to Assay Facilitates Identification of Phenotypic Changes and Produces Predictive Assays Associated With a Variety of Cancer Types and Potential Therapies FREMONT, Calif., April 18 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (NASDAQ:CIPH) announced today that 44 studies involving its proprietary SELDI ProteinChip(R) Technology will be presented at the 96th Annual American Association of Cancer Research (AACR) conference in Anaheim, CA., April 16-20. Leading researchers are presenting biomarker discovery, validation, identification and assay development progress across a wide variety of cancers and therapeutic strategies enabled by the use of SELDI ProteinChip technology. Presentations made by Ciphergen's customers cover such fields as serum proteome profiling, metastasis prognosis, cancer therapeutics and monitoring drug response. Biomarker discovery and identification will be described for a broad range of cancer types including breast, colon, prostate, pancreatic, lung, head and neck, ovarian, and several other cancers. An example of the potential for Ciphergen's proprietary technology was demonstrated in a study from researchers at the University of Pittsburgh Cancer Institute titled, "Serum SELDI-TOF-MS Protein Profiling and Classification in Women with Estrogen Receptor Positive Breast Infiltrating Ductal Carcinoma." Using Ciphergen's SELDI ProteinChip technology including the CiphergenExpress and Biomarker Patterns Software for peak clustering and classification, researchers were able to discover protein biomarkers and produce an assay with good sensitivity and specificity that distinguishes a breast cancer population (n=48) from patients with benign breast lesions (n=47) and from healthy controls (n=48). Ciphergen Diagnostics, a division of Ciphergen Biosystems, Inc., is working with many of these leading researchers to translate their discoveries into clinically viable assay products that can be used to improve patient care. "This study and the many others that will be featured at AACR demonstrate the potential for improving patient care by discovering novel biomarkers and patterns of biomarkers and developing them into potential diagnostic and theranostic tests based on Ciphergen's SELDI ProteinChip(R) Technology," said William Rich, President & CEO of Ciphergen. The AACR Annual Meeting is well known for the quality of its outstanding program. More than 15,000 participants from 60 countries gather to discuss over 6,000 abstracts and to hear more than 250 invited presentations on new and significant discoveries in basic, clinical, and translational cancer research. The AACR Program Committee identifies the most compelling science and ensures that the latest advances in all areas of cancer research and specifically the most important emerging research fields are fully covered. Ciphergen is proud to be among one of the important emerging technologies that is being used to further cancer research. About Ciphergen Ciphergen's Biosystems Division develops, manufactures and markets a family of ProteinChip(R) Systems and services for clinical, research, and process proteomics applications. ProteinChip Systems enable protein discovery, characterization, identification and assay development to provide researchers with predictive, multi-marker assay capabilities and a better understanding of biological function at the protein level. Ciphergen's Diagnostics Division is dedicated to the discovery of protein biomarkers and panels of biomarkers and their development into protein molecular diagnostic tests that improve patient care; and to providing collaborative R&D services through its Biomarker Discovery Center(R) laboratories for biomarker discovery for new diagnostic tests as well as pharmacoproteomic services for improved drug toxicology, efficacy and theranostic assays. Additional information about Ciphergen can be found at http://www.ciphergen.com/. Safe Harbor Statement Note Regarding Forward-Looking Statements: For purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such forward-looking statements include statements regarding the potential development of diagnostic and theranostic tests that improve patient care and the providing of pharmacoproteomic services for improved drug toxicology, efficacy and theranostic assays. Actual results may differ materially from those projected in such forward-looking statements due to various factors, including the risk that Ciphergen will not be able to validate biomarker discoveries and develop diagnostic or theranostic tests that meet with commercial acceptance or that improve drug development. Investors should consult Ciphergen's filings with the Securities and Exchange Commission, including its Form 10-K dated March 22, 2005, for further information regarding these and the other risks of the Company's business. NOTE: Ciphergen, ProteinChip and Biomarker Discovery Center are registered trademarks of Ciphergen DATASOURCE: Ciphergen Biosystems, Inc. CONTACT: Sue Carruthers, Investor Relations of Ciphergen Biosystems, Inc., +1-510-505 2297 Web site: http://www.ciphergen.com/

Copyright